#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chemical burn Granulomatosis with polyangiitis Familial amyotrophic lateral sclerosis Anal fistula Bronchiolitis Synovial sarcoma Idiopathic pulmonary fibrosis Fibrous dysplasia of bone B-cell small lymphocytic lymphoma refractory Anti-neutrophil cytoplasmic antibody positive vasculitis Hepatic angiosarcoma Glioma Extraskeletal ossification Post transplant lymphoproliferative disorder Cryoglobulinaemia More trials…

    Learn about Rare Diseases

    Mast cell activation syndrome – Diagnostics Inclusion body myositis Leiomyosarcoma recurrent – Treatment Splenic marginal zone lymphoma – Diagnostics MELAS syndrome – Basic Information Langerhans cell sarcoma Osteosarcoma metastatic Haemophilia – Treatment Ehlers-Danlos syndrome – Basic Information Angelman’s syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ipratropium Bromide Magnesium Gallium (68Ga) Tiragolumab CHONDROITIN SULFATE SODIUM Mbf-015 Rezpegaldesleukin OLVEREMBATINIB Ethambutol ACT-1004-1239 NAVENIBART Eprosartan Mesilate Furosemide Lanifibranor Sym025 SP16 Xaluritamig Immunoglobulin M Octreotide Acetate ELTANEXOR More therapies…

    Learn about Your Condition

    Vulvovaginal candidiasis Carotid artery stenosis B-cell lymphoma recurrent Acute kidney injury Toxic epidermal necrolysis Bladder cancer recurrent Urinary incontinence Drug eruption Dyspepsia Juvenile psoriatic arthritis Intestinal obstruction Plasma cell leukaemia Adenocarcinoma of colon Rhabdomyosarcoma recurrent Primary myelofibrosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study of brentuximab vedotin for maintenance therapy in patients with cutaneous T-cell lymphoma after stem cell transplant

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Cutaneous T-cell lymphoma
    Investigated Drugs:
    • Brentuximab Vedotin
    France

  • Comparing amoxicillin-clavulanate alone versus amoxicillin-clavulanate with ciprofloxacin for treating chemotherapy-induced fever in adult hematology patients

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Amoxicillin Sodium
    • Ciprofloxacin Hydrochloride
    • Clavulanic Acid
    France

  • Study of CMP-CPS-001 injection in healthy volunteers and patients with abnormal ornithine transcarbamylase (OTC) genotype for treating urea cycle disorders

    Not yet recruiting

    1 1
    Investigated Diseases:
    • Urea cycle disorder
    Investigated Drugs:
    • AMMONIUM (15N) CHLORIDE
    • Sodium Acetate (1-13C)
    The Netherlands

  • Study comparing 3-week versus 6-week antibiotic treatment for patients with drained pyogenic liver abscess

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Cilastatin
    • Avibactam
    • Ceftazidime
    France

  • Evaluating shorter duration of pembrolizumab and pemetrexed treatment in patients with metastatic non-small cell lung cancer who have not progressed after 6 months

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Pembrolizumab
    • Pemetrexed
    The Netherlands

  • Study of semaglutide effects on inflammation markers in patients with type 2 diabetes mellitus who have high cardiovascular risk

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Semaglutide
    Italy
Previous Page
1 … 789 790 791 792 793 … 1,673
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!